Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

New Implications of the Mosunetuzumab Data & What it Means for Patients with DLBCL

Get a First Class Intelligence Report to Solidify Your Strategy

Although regimens in the last decade have proven curative for most patients with diffuse large B-cell lymphoma (DLBCL), a considerable proportion require additional treatment. Novel therapies have constantly been introduced in the treatment landscape of DLBCL.

It is debatable as to whether these regimens remain “the” standard of care, or if they have now become “a” standard of care.

Mosunetuzumab is a T-cell engaging bispecific IgG antibody currently being developed for multiple types of lymphatic cancers.

Updated results for two trials were presented at the the American Society of Hematology (ASH): a phase I/II trial evaluating mosunetuzumab monotherapy in previously untreated older/unfit patients with DLBCL; and a subgroup analysis of a phase Ib/II trial evaluating mosunetuzumab in combination with polatuzumab in patients with relapsed/refractory DLBCL.

Excited by the results presented at ASH, the NoeticInsight team rapidly gathered expert opinions on the future of the DLBCL. Through our virtual blinded platform, we easily connected with leaders in the field of lymphatic cancers who were able to share their honest and robust opinions.

Complete the form to get your copy of this valuable report.

New Implications of the Mosunetuzumab Data Presented at ASH 2022 & What it Means for Patients with DLBCL




    Get in touch

    Please leave your information and we’ll reach out within 24 hours.